Clinical Trial Update: Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether Symbicort (budesonide/formoterol) improves exercise tolerance in patients with severe chronic obstructive pulmonary disease, co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Oxis
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED | Results posted: 2012-08-30